Certara Inc (CERT) Q1 2026 Earnings Call Transcript

Why It Matters

The results demonstrate Certara’s accelerating adoption of its biosimulation platform, positioning it to capture a larger share of biopharma R&D spend and to sustain high‑margin growth. Its product innovations and geographic reach deepen its competitive moat in a market that increasingly relies on virtual drug development tools.

Key Takeaways

• Revenue up 16% YoY to $66.7M.
• Bookings grew 34% YoY, services bookings +39%.
• Software version 20 launched, adding maternal health models.
• New Shanghai office supports Asia Pacific expansion.
• Adjusted EBITDA rose 20% to $23.9M.

Pulse Analysis

Certara’s Q1 performance underscores a broader shift in pharmaceutical R&D toward computational drug development. By delivering a 16% revenue increase and a 20% jump in adjusted EBITDA, the firm proved that its end‑to‑end biosimulation platform can generate scalable, high‑margin revenue streams even as the industry recovers from pandemic disruptions. The strong booking growth—34% overall and 39% in services—reflects deepening relationships with existing customers and successful acquisition of new biotech partners, reinforcing Certara’s position as a go‑to provider for both small‑molecule and biologics projects.

Product innovation remains a core growth driver. The release of Simcyp version 20 introduced advanced maternal‑health and virtual bioequivalence models, enabling sponsors to bypass costly clinical studies and accelerate time‑to‑market. The launch of Secondary Intelligence, the only software that predicts off‑target safety issues early, addresses a critical failure point—safety‑related attrition accounts for roughly a quarter of drug‑program terminations. These tools not only expand Certara’s addressable market but also deepen its value proposition, positioning the company at the forefront of mechanistic modeling and risk mitigation in drug discovery.

Financially, Certara’s updated 2021 guidance—revenues of $277‑$285 million and adjusted EBITDA of $100‑$102 million—signals confidence in sustaining mid‑teens revenue growth while improving margin trajectories. The firm’s robust cash position ($273 million) and manageable debt profile provide flexibility for continued R&D investment and strategic acquisitions. Expansion in Europe and a rapidly scaling Shanghai office highlight a deliberate global footprint aimed at capturing growth in high‑potential regions. As biopharma firms increase spending on virtual development platforms, Certara’s integrated software‑services model is well‑placed to benefit from the accelerating digital transformation of drug development.